These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17893270)

  • 1. The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma.
    Mackenzie IS; Gurnell M; Balan KK; Simpson H; Chatterjee K; Brown MJ
    Eur J Endocrinol; 2007 Oct; 157(4):533-7. PubMed ID: 17893270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG PET in the evaluation of phaeochromocytoma: a correlative study with MIBG scintigraphy and Ki-67 proliferative index.
    Lin M; Wong V; Yap J; Jin R; Leong P; Campbell P
    Clin Imaging; 2013; 37(6):1084-8. PubMed ID: 24035263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
    Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
    Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDOPA PET Compared With 123I-Metaiodobenzylguanidine Scintigraphy and 18F-FDG PET in Secreting Sporadic Pheochromocytoma.
    Lugat A; Drui D; Mirallié E; Kraeber-Bodéré F; Ansquer C
    Clin Nucl Med; 2019 Sep; 44(9):738-740. PubMed ID: 31306205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.
    Rufini V; Treglia G; Castaldi P; Perotti G; Calcagni ML; Corsello SM; Galli G; Fanti S; Giordano A
    Nucl Med Commun; 2011 Jul; 32(7):575-82. PubMed ID: 21471850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
    Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
    J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MIBG and FDG PET findings in a patient with malignant pheochromocytoma: a significant discrepancy.
    Ezuddin S; Fragkaki C
    Clin Nucl Med; 2005 Aug; 30(8):579-81. PubMed ID: 16024963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adrenal incidentaloma and nuclear medicine examination].
    Tenenbaum F
    J Radiol; 2009 Mar; 90(3 Pt 2):444-8. PubMed ID: 19421135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.
    Kroiss A; Putzer D; Uprimny C; Decristoforo C; Gabriel M; Santner W; Kranewitter C; Warwitz B; Waitz D; Kendler D; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):865-73. PubMed ID: 21279352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of a Pheochromocytoma With TNEM127 Mutation Negative on 18F-FDOPA and 18F-FDG but Positive on 123I-MIBG and 68Ga-DOTATOC Imaging.
    Cottereau AS; Garcia C; Dousset B; Libe R; Tenenbaum F
    Clin Nucl Med; 2022 Mar; 47(3):251-252. PubMed ID: 34507330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Case of 131I-meta-iodobenzylguanidine (MIBG) scintigraphy-negative and 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)-positive pheochromocytoma].
    Jotoku M; Okura T; Nagao T; Enomoto D; Irita J; Miyoshi K; Kurata M; Fukuoka T; Higaki J
    Nihon Jinzo Gakkai Shi; 2009; 51(5):563-8. PubMed ID: 19715165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience.
    Win Z; Al-Nahhas A; Towey D; Todd JF; Rubello D; Lewington V; Gishen P
    Nucl Med Commun; 2007 May; 28(5):359-63. PubMed ID: 17414885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma.
    Mann GN; Link JM; Pham P; Pickett CA; Byrd DR; Kinahan PE; Krohn KA; Mankoff DA
    Ann Surg Oncol; 2006 Feb; 13(2):187-97. PubMed ID: 16418883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography for the assessment of 131I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma.
    Nakazawa A; Higuchi T; Oriuchi N; Arisaka Y; Endo K
    Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1869-75. PubMed ID: 21732103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 123I-metaiodobenzylguanidine scans in phaeochromocytoma diagnosis: current clinical practice and relationship to biochemical screening.
    Tormey WP; Keeling F; Lee MJ
    Int J Clin Pract; 1999 Sep; 53(6):428-32. PubMed ID: 10622069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does iodine-131 meta-iodobenzylguanidine (MIBG) scintigraphy have an impact on the management of sporadic and familial phaeochromocytoma?
    Taïeb D; Sebag F; Hubbard JG; Mundler O; Henry JF; Conte-Devolx B
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):102-8. PubMed ID: 15212651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic localization of pheochromocytoma: the coming of age of positron emission tomography.
    Pacak K; Eisenhofer G; Carrasquillo JA; Chen CC; Whatley M; Goldstein DS
    Ann N Y Acad Sci; 2002 Sep; 970():170-6. PubMed ID: 12381552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome.
    Kaji P; Carrasquillo JA; Linehan WM; Chen CC; Eisenhofer G; Pinto PA; Lai EW; Pacak K
    Eur J Endocrinol; 2007 Apr; 156(4):483-7. PubMed ID: 17389464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.